QUALITY OF LIFE OF PATIENTS WITH VITILIGO AND THE INFLUENCE OF MODERN THERAPY METHODS

Article Sidebar

PDF (Russian)
Published: 2025-12-05
DOI: https://doi.org/10.66073/researchfocus.v4i11.1874
Keywords:
vitiligo, quality of life, DLQI, VitiQoL, VASI, NB-UVB, tacrolimus, JAK inhibitors, ruxolitinib, tofacitinib, psychoemotional state, HADS, dermatology, clinical efficacy

Main Article Content

Nasridinov Farijon Abduraimovich
Samarkand Regional Branch of the Republican Specialized Scientific and Practical Medical Center of Dermatovenerology and Cosmetology. Uzbekistan, Samarkand, Panjikent street 404
Tolibov Mansur Maxmudovich
Samarkand State Medical University. Uzbekistan, Samarkand, Amir Temur street, 18

Abstract

This study assesses the influence of modern methods of therapy on the quality of life of patients with vitiligo in order to determine the most effective approach in terms of clinical and psychosocial outcome. The analysis was carried out by comparing three therapeutic groups. On the basis of data from clinical indices and validated questionnaires, changes in quality-of-life indicators and their relationship with the degree of repigmentation were determined. The dynamics of the clinical severity of the disease and the parameters of the psycho-emotional state were analysed using statistical methods. In addition, the level of patient satisfaction with the various types of treatment was calculated, which is an important integral indicator of the effectiveness of therapy.

Article Details

Issue

Vol. 4 No. 11 (2025): Research Focus International Scientific Journal. Volume 4, Issue 11 (2025)

Section

14.00.00 – Medical sciences
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

QUALITY OF LIFE OF PATIENTS WITH VITILIGO AND THE INFLUENCE OF MODERN THERAPY METHODS. (2025). Research Focus International Scientific Journal, 4(11), 321-326. https://doi.org/10.66073/researchfocus.v4i11.1874

References

Taïeb A., Picardo M. Vitiligo. N Engl J Med. 2009;360(2):160–169.

Ezzedine K., Eleftheriadou V., Whitton M., van Geel N. Vitiligo. Lancet. 2015;386(9988):74–84.

Krüger C., Schallreuter K.U. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51(10):1206–1212.

Porter J.R., Beuf A., Nordlund J.J., Lerner A.B. Psychological reaction to chronic skin disorders. Arch Dermatol. 1979;115:1014–1015.

Mattoo S.K., Handa S., Kaur I. Psychiatric morbidity in vitiligo. J Dermatol. 2002;29:448–452.

Pahwa P., Mehta M., Khaitan B.K. Psychosocial impact of vitiligo. Dermatol Clin. 2017;35(2):257–265.

Harris J.E. Cellular stress and autoimmunity in vitiligo. Curr Opin Immunol. 2016;43:25–30.

Schallreuter K.U., Moore J., Wood J.M. Involvement of oxidative stress in vitiligo. Clin Exp Dermatol. 2012;37(4):425–430.

Van den Boorn J.G., Picavet D.I., van Swieten P.F. Skin-homing cytotoxic T lymphocytes in vitiligo. J Invest Dermatol. 2009;129(8):2058–2067.

Speeckaert R., Speeckaert M.M., van Geel N. Vitiligo: an update on pathophysiology and treatment options. Am J Clin Dermatol. 2017;18(6):733–744.

Jin Y., Birlea S.A., Fain P.R. Genome-wide association studies of vitiligo. Nat Genet. 2010;42(7):614–618.

Ongenae K., Van Geel N., Naeyaert J.M. Quality of life and stigmatization in vitiligo. Pigment Cell Res. 2005;18: 110–111.

Amerio P., Carbone A., Auriemma M. Depression and anxiety in vitiligo: correlation with clinical severity. Clin Exp Dermatol. 2004;29(6):684–685.

Talsania N., Lamb B., Bewley A. Quality of life and vitiligo: results from a UK study. Br J Dermatol. 2010;163: 124–126.

Finlay A.Y., Khan G.K. Dermatology Life Quality Index (DLQI). Clin Exp Dermatol. 1994;19:210–216.

Ongenae K., Beelaert L., Van Geel N. Vitiligo and quality of life. J Eur Acad Dermatol Venereol. 2006;20:1–8.

Lilly E., Lu P.D., Borovicka J.H. Development of Vitiligo-specific Quality of Life (VitiQoL) questionnaire. J Am Acad Dermatol. 2013;69(1):e144–e153.

Yones S.S., Palmer R.A., Garibaldinos T.M., Hawk J.L. Randomized trial of narrow-band UVB vs PUVA therapy. Lancet. 2007;360: 110–115.

Lepe V., Moncada B., Valencia I. Topical tacrolimus for vitiligo of the face. Br J Dermatol. 2003;149: 45–49.

Rosmarin D., Pandya A.G., Lebwohl M. Ruxolitinib cream for the treatment of vitiligo. N Engl J Med. 2020;383: 1445–1455.

Liu L.Y., Strassner J.P., Refat M.A. IFN-γ–CXCL10 pathway in vitiligo: therapeutic implications. J Invest Dermatol. 2020;140(4): 788–795.

Craiglow B.G., King B.A. Tofacitinib treatment of vitiligo. J Am Acad Dermatol. 2015;72(5): 880–882.

Rothstein B., Joshipura D., Saraiya A. Use of JAK inhibitors for vitiligo. J Dermatol Sci. 2019;94(1): 18–26.

Eleftheriadou V., Thomas K., van Geel N. Measuring outcomes in vitiligo clinical trials. J Am Acad Dermatol. 2021;84(6): 1433–1442.

Rodrigues M., Ezzedine K., Hamzavi I. New insights into vitiligo: patient-centered outcomes. J Am Acad Dermatol. 2017;77(1):1–13.